PCSK9 Inhibitors in Practice: Real-World Strategies for Cardiovascular Risk Reduction [Baltimore]
September 17, 2019
P. Barton Duell, MD, FNLA, FAHA
Professor of Medicine, Director of Lipid-Atherosclerosis Laboratory
Knight Cardiovascular Institute, OHSU
Dr. Duell’s special areas of interest include lipid disorders (e.g. high cholesterol), metabolic disorders, homocysteine metabolism, prevention of atherosclerosis (heart disease), diabetes, endocrinology and management of obesity. He currently serves as the director of OHSU’s Metabolic Disorders Clinic. He received his medical degree from OHSU in 1983, and completed his medicine residency at OHSU and the University of Chicago. He completed his metabolism, endocrinology and nutrition fellowship at the University of Washington in Seattle.
Disclosure - Dr. P. Barton Duell has served as a Consultant for Akcea, Astra Zeneca, Regeneron, Regenxbio, Esperion, and Retrophin. Institutional Grants were received from Regeneron, Regenxbio, Esperion and Retrophin.
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC
Associate Professor of Medicine (Cardiology)
Johns Hopkins University School of Medicine
Dr. Martin is a core faculty member in the Ciccarone Center for the Prevention of Cardiovascular Disease and Director of the Advanced Lipid Disorders Center. Dr. Martin also serves as an Associate Faculty member in the Welch Center for Prevention, Epidemiology, and Clinical Research. He has a longstanding passion for preventive cardiology, in particular, cardiovascular risk assessment, lipidology, and mobile health technology. Dr. Martin has published more than 170 articles in leading cardiology and medicine journals, as well as 15 book chapters. He serves as Associate Editor for the American College of Cardiology’s Dyslipidemia Clinical Community and as an Associate Editor for the Journal of Clinical Lipidology.
Dr. Martin was selected as one of 125 faculty members, fellows, postdocs, staff and students who personify Johns Hopkins Medicine’s mission to improve the health of the community and the world by setting the standard of excellence in medical education, research and clinical care, in celebration of the 125th Johns Hopkins Medicine anniversary.
Disclosure - Dr. Seth Martin has served on an Advisory Board for Amgen, Sanori and Regeneron.
Gregory Pokrywka, MD, FACP, FNLA, FASPC, NCMP
Assistant Professor of General Internal Medicine
Johns Hopkins University School of Medicine
Gregory Pokrywka MD FACP FNLA FASPC NCMP is a Board-Certified Internist from Baltimore/Towson, Md. He attended Duke University, worked as a biochemist, attended the University of Maryland Medical School and was Chief Resident in Internal Medicine at Mercy Hospital, Baltimore. He has been in private practice since 1987 and formed the Baltimore Lipid Center in 2001. Dr. Pokrywka has further pursued his interest in Menopausal Lipidology through certification as a Credentialed Menopause Practitioner by the North American Menopause Society (NAMS). He is a November 2005 Inaugural Diplomate of the American Board of Clinical Lipidology (“Board Certified in Clinical Lipidology”) and is one of a handful of U.S physicians double-certified in Menopause and Lipidology. In March of 2009 Dr. Pokrywka was elected by his peers to the honor of “Fellow of the National Lipid Assn.” (FNLA) Fellowship in the National Lipid Association recognizes the excellence, innovation, and leadership of health professionals in the NLA with respect to Clinical Lipidology in private practice or academic settings. Fellowship is reserved for NLA members who have made significant regional and/or national contributions to the science and practice of Clinical Lipidology. In August 2016 Dr. Pokrywka was among the first physicians elected by his peers as a Fellow of the American Society of Preventive Cardiology (ASPC). This honor recognizes excellence, innovation, and leadership in preventive cardiology.
Dr. Pokrywka now serves as Assistant Professor for the Johns Hopkins University School of Medicine. In 11/2011 Dr. Pokrywka completed a DATA 2000 compliant buprenorphine training program, and regularly treats opiate abuse patients, both in his own practice and as a Medical Director for First Step, and MATCinic, Baltimore. He has also participated in over 25 Clinical Trials with the IRC Clinical Research Center, and CPG Clinical Research of Towson, MD, as a Sub-Investigator and Principal Investigator, since 2012.
Dr. Pokrywka is a member of the American Heart Association Council on Atherosclerosis, the National Lipid Association (NLA), the International and the European Atherosclerosis Societies, the American Society of Preventive Cardiology, the Androgen Excess and PCOS Society, the Obesity Society, the Familial HyperCholesterolemia Foundation, the Lipoprotein(a) Foundation, and is a Fellow of the American College of Physicians. He participates enthusiastically in the Go Red for Women and WomenHeart campaigns to fight heart disease in women. He was elected to serve as a member of the Board of Directors of the Southeast Lipid Assn., 2009-2019, serves as NLA Regional Representative, and Vice-Chair of the NLA Membership Committee. Lecturing nationwide since 2001, Dr. Pokrywka has conducted since 2002 over 100 lipid / lipoprotein educational programs per year. He has lectured in 44 states to Internists/FP’s, Cardiologists, Ob/Gyns, Nurse Midwives, Physician’s Assts. and Nurse Practitioners at hospital and medical school grand rounds, CME programs, national tele- and web-conferences and multiple other venues on “Aggressive Detection and Prevention of ASCVD in Insulin Resistant Women” and “Women’s Menopausal Health.” Other areas of interest include “Advanced Lipoprotein Testing”, “Treatment of the Metabolic Syndrome”, “HDL Cholesterol”, “Diagnosis and Treatment of Hypertriglyceridemia”, “Cardiovascular Effects of Estrogen and Estrogen Receptor Modification”, “Diabetic Dyslipidemia”, PCOS and Cardiovascular Risk” and “Osteoporosis: Prevention and Treatment”.
Dr. Pokrywka has served for years on the Editorial Board of the Journal of Clinical Lipidology, and was promoted to Associate Editor in 2017. In 2010 Dr. Pokrywka became the first NLA Fellow to offer both in-office Carotid IMT testing for the detection of subclinical atherosclerosis, as well as a CardioMetabolic Disease reduction / wellness program in partnership with Metagenics, Inc. (“FirstLine Therapy”) and Board Certified Clinical Nutritionists. Dr. Pokrywka serves on the National Lecture Bureaus of multiple pharmaceutical companies.